Vanguard Group
APLT

Vanguard Group’s Applied Therapeutics APLT Stock Holding History

Vanguard Group’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$635K Buy
6,353,018
+1,250,329
+25% +$794K ﹤0.01% 3890
2025
Q3 		$3.09M Buy
5,102,689
+368,676
+8% +$174K ﹤0.01% 3428
2025
Q2 		$1.47M Sell
4,734,013
-1,155,180
-20% -$447K ﹤0.01% 3637
2025
Q1 		$2.88M Buy
5,889,193
+340,962
+6% +$201K ﹤0.01% 3363
2024
Q4 		$4.75M Buy
5,548,231
+305,282
+6% +$1.91M ﹤0.01% 3292
2024
Q3 		$44.6M Sell
5,242,949
-79,511
-1% -$469K ﹤0.01% 2227
2024
Q2 		$24.9M Buy
5,322,460
+2,312,170
+77% +$10.9M ﹤0.01% 2459
2024
Q1 		$20.5M Sell
3,010,290
-220,191
-7% -$989K ﹤0.01% 2584
2023
Q4 		$10.8M Buy
3,230,481
+1,801,827
+126% +$4.48M ﹤0.01% 2901
2023
Q3 		$3.56M Buy
1,428,654
+431,652
+43% +$711K ﹤0.01% 3388
2023
Q2 		$1.28M Buy
997,002
+141,847
+17% +$188K ﹤0.01% 3824
2023
Q1 		$694K Buy
855,155
+58,593
+7% +$57.7K ﹤0.01% 4021
2022
Q4 		$605K Buy
796,562
+343,299
+76% +$272K ﹤0.01% 4048
2022
Q3 		$422K Sell
453,263
-60,956
-12% -$73.1K ﹤0.01% 4258
2022
Q2 		$488K Sell
514,219
-96,648
-16% -$158K ﹤0.01% 4303
2022
Q1 		$1.29M Sell
610,867
-240,271
-28% -$644K ﹤0.01% 4129
2021
Q4 		$7.62M Buy
851,138
+839
+0.1% +$11K ﹤0.01% 3380
2021
Q3 		$14.1M Buy
850,299
+5,417
+0.6% +$93.5K ﹤0.01% 3052
2021
Q2 		$17.6M Buy
844,882
+10,713
+1% +$203K ﹤0.01% 2915
2021
Q1 		$15.6M Buy
834,169
+152,605
+22% +$3.29M ﹤0.01% 2920
2020
Q4 		$15M Buy
681,564
+887
+0.1% +$18.5K ﹤0.01% 2782
2020
Q3 		$14.1M Buy
680,677
+65,157
+11% +$1.69M ﹤0.01% 2611
2020
Q2 		$22.3M Buy
615,520
+67,462
+12% +$2.82M ﹤0.01% 2370
2020
Q1 		$17.9M Buy
548,058
+208,162
+61% +$8.42M ﹤0.01% 2346
2019
Q4 		$9.27M Buy
339,896
+304,932
+872% +$5.22M ﹤0.01% 2895
2019
Q3 		$384K Buy
+34,964
New +$330K ﹤0.01% 3868

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's APLT Position: Q4 2025 in Review

Vanguard Group increased its Applied Therapeutics (APLT) stake by 25% in Q4 2025, buying an estimated $794K and bringing the position to 6,353,018 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #3890.

Vanguard Group first reported a position in APLT in Q3 2019 and has held it in 26 quarters since. The position peaked at $44.6M in Q3 2024. 52 funds tracked by Wall St. Rank hold APLT as of Q4 2025.

  • Vanguard Group held 6,353,018 shares of Applied Therapeutics worth $635K as of Q4 2025.
  • Vanguard Group bought 1,250,329 Applied Therapeutics shares in Q4 2025, an estimated $794K.
  • Applied Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3890 holding.
  • Vanguard Group first reported a position in Applied Therapeutics in Q3 2019 and has held it in 26 quarters since.
  • Vanguard Group's Applied Therapeutics position peaked at $44.6M in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Applied Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.